Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Legendary Trader Peter Brandt Names Bullish XRP Target

Legendary Trader Peter Brandt Names Bullish XRP Target

UTodayUToday2026/10/06 11:51

The trader believes there is an emerging technical formation that could lead to the aforementioned bullish price target for the cryptocurrency.

A promising pattern 

The seasoned chartist stated he is seeing a cup-and-handle technical formation on the XRP chart. 

On a larger timeframe, it could also be the right shoulder of an inverse head-and-shoulders pattern.

Brandt says XRP price could hit $2.16 if the emerging technical pattern he's tracking ends up playing out. 

He set a potential $2.16 price target based on taking the height of this inverse head-and-shoulders formation on a daily closing price chart and extending it upwards.

Given that XRP is currently trading near $1.50, it would mean the token would need to rally around 44% for it to hit Brandt's potential price target.

However, technical patterns often don't hit their initial targets or sometimes transform into something entirely different.

The veteran trader explained he is a believer in the idea of "measured moves." 

Brandt also noted that this potential right shoulder of the technical pattern is "poorly formed" and "abbreviated." This could indicate that more of the right shoulder is still forming, but not necessarily.

Major XRP obstacle

Looking at a weekly chart, Brandt pointed out that XRP price is well off the major peaks from the previous rally. There could be a lot of holders at higher price levels that could sell as XRP goes higher, forming resistance.

"There is a TON of overhead supply to go through," said Brandt. He called it a negative for XRP.

The trader compared XRP to a number of other major cryptocurrencies. He claimed that Monero (XMR) has already worked through a lot of its overhead supply. He also said Solana shows a much better-looking cup-and-handle technical formation.

At the time of writing, XRP is trading around $1.50 and has a market cap of around $94.65 billion, per the provided CoinGecko data. Over the past month, XRP is up around 5.5%.  

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Monnalisa shares delist from Euronext Growth Milan

Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/06 16:04

Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted

Updated stock data and added analyst comments in paragraphs 8 and 10 Christy Santhosh - Reuters, October 6 - ArriVent BioPharma (AVBP.O) announced on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, causing the company's share price to plunge by nearly 60% in early trading. The therapy, firmonertinib, was tested in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients carrying a gene mutation known as EGFR exon 20 insertion, which may promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC makes up around 85% of all lung cancer cases. An assessment by independent reviewers showed that ArriVent’s 240 mg dose therapy extended median progression-free survival to 11 months in the trial, compared to just 9.5 months for the chemotherapy group. CEO Bing Yao stated that the improvement in progression-free survival (i.e., the period during which a patient's cancer does not worsen or spread) was not "significant". "These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options." The company said it is reviewing the complete dataset to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial. BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed was the control group's performance exceeding expectations—their progression-free survival reached 9.5 months, when only 7.5 to 8 months was anticipated; firmonertinib’s 11-month result matched the expected range of 9 to 11 months. Additionally, firmonertinib is currently undergoing an advanced clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors. "This result is a significant setback for the exon 20 mutation treatment space, but the PACC program still has clinical support," said Clear Street analyst Kaveri Pohlman. The therapy has been approved in China for NSCLC patients carrying specific mutations. (To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and they are provided for reader convenience only. Reuters is not responsible for any damages or losses arising from the use of automated translation features.)

路透社•2026/10/06 15:18
Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted